No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY trial

Investigators report no significant difference in the primary endpoint of 28-day mortality (22.1% lopinavir-ritonavir vs. 21.3% usual care; relative risk 1.04 [95% CI 0.91-1.18]; p=0.58).

Source:

Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial